window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-64619718-7');

S65487

Background

The B-cell lymphoma 2 (Bcl-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member Bcl-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukaemia.

 

Clinical studies

Servier collaborates with Novartis for the clinical development of S65487. The candidate is currently being tested to assess safety, tolerability, pharmacokinetic and preliminary clinical activity and to estimate the maximum tolerated doses )/ recommended Phase 2 doses as single agent administered intravenously in adult patients with refractory or relapsed acute myeloid leukaemia, non-Hodgkin lymphoma, multiple myeloma or chronic lymphocytic leukaemia.

2021-02-02T12:21:34+00:00February 2nd, 2021|